Actively Recruiting
SCOPE Analytic Treatment Interruption Protocol
Led by University of California, San Francisco · Updated on 2026-01-23
40
Participants Needed
1
Research Sites
398 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
C
Chan Zuckerberg Biohub
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.
CONDITIONS
Official Title
SCOPE Analytic Treatment Interruption Protocol
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to provide written informed consent
- Age 18 years or older
- Documented HIV infection
- On antiretroviral therapy for at least 12 months
- Screening plasma HIV RNA levels below detection (<40-75 copies/mL) and past 12 months also below detection (blips allowed)
- Screening CD4+ T-cell count over 350 cells/uL
- If able to become pregnant, willing to use two methods of contraception
- Willing to receive counseling about reducing HIV transmission risk
You will not qualify if you...
- Pregnant or planning pregnancy during the study
- Active hepatitis B infection
- Active hepatitis C infection
- Use of a non-nucleoside reverse transcriptase inhibitor and unable to change treatment
- Significant heart or brain blood vessel disease
- Cancer within the past 5 years
- Severe kidney disease (creatinine clearance under 50 mL/min)
- Severe liver impairment (Child-Pugh Class C) or unstable liver disease
- Currently receiving immunomodulatory drugs
- Unable or unwilling to use barrier protection or PrEP to prevent HIV transmission to partners not known to have HIV
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California San Francisco
San Francisco, California, United States, 94110
Actively Recruiting
Research Team
S
Steven Deeks, MD
CONTACT
M
Michael Peluso, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here